- Home
- VTYX vs RDCM Comparison
VTYX vs RDCM Comparison
Compare VTYX & RDCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- RDCM
- Stock Information
- Founded
- VTYX 2018
- RDCM 1985
- Country
- VTYX United States
- RDCM Israel
- Employees
- VTYX N/A
- RDCM N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- RDCM Computer peripheral equipment
- Sector
- VTYX Health Care
- RDCM Technology
- Exchange
- VTYX Nasdaq
- RDCM Nasdaq
- Market Cap
- VTYX 154.9M
- RDCM 179.5M
- IPO Year
- VTYX 2021
- RDCM 1997
- Fundamental
- Price
- VTYX $1.07
- RDCM $11.62
- Analyst Decision
- VTYX Buy
- RDCM Strong Buy
- Analyst Count
- VTYX 4
- RDCM 2
- Target Price
- VTYX $11.33
- RDCM $15.00
- AVG Volume (30 Days)
- VTYX 731.3K
- RDCM 41.5K
- Earning Date
- VTYX 05-08-2025
- RDCM 05-14-2025
- Dividend Yield
- VTYX N/A
- RDCM N/A
- EPS Growth
- VTYX N/A
- RDCM 79.17
- EPS
- VTYX N/A
- RDCM 0.43
- Revenue
- VTYX N/A
- RDCM $61,009,000.00
- Revenue This Year
- VTYX N/A
- RDCM $14.93
- Revenue Next Year
- VTYX N/A
- RDCM $10.74
- P/E Ratio
- VTYX N/A
- RDCM $26.58
- Revenue Growth
- VTYX N/A
- RDCM 18.23
- 52 Week Low
- VTYX $1.07
- RDCM $8.52
- 52 Week High
- VTYX $5.66
- RDCM $15.98
- Technical
- Relative Strength Index (RSI)
- VTYX 23.19
- RDCM 42.88
- Support Level
- VTYX $1.28
- RDCM $11.35
- Resistance Level
- VTYX $1.37
- RDCM $13.00
- Average True Range (ATR)
- VTYX 0.08
- RDCM 0.58
- MACD
- VTYX -0.01
- RDCM -0.02
- Stochastic Oscillator
- VTYX 0.00
- RDCM 21.59
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.